Introduction
The chronic rejection of transplanted organs is the major and still unresolved problem in transplantation. Although phenomenon of chronic rejection, by virtue of its complexity and multifactoriality is still not well understood, it is known that monocytes and macrophages play an important role in this process (1) (2) .
Mammalian organs (including heart) contain various subsets of macrophages with different origin (embryonic yolk sack versus blood or bone marrow-derived) and functions (3) (4) (5) (6) . The injury or other organ/tissue stress, including transplantation, drives the production of bone marrow-derived monocytes, which via circulation enter target organ/tissue where they differentiate into dendritic cells and macrophages (7). The subset of these monocyte/macrophages, expressing high level of chemokine receptor CX3CR1 is specifically targeted to the endothelium of blood vessel walls, which produce high level of CX3CL1 chemokine (fractalkine; (7-8). Interestingly, one of the hallmarks of chronic rejection is the remodeling (through the over-proliferation and differentiation of smooth muscle cells) of the arterial walls, resulting in neointimal hyperplasia, vessel occlusion and eventual failure of the graft (9, 10) . The smooth muscle over-proliferation and differentiation during neointimal hyperplasia as well as development of atherosclerotic plaque depend selectively on CX3CR1 expressing monocytes and CX3CR1/CXC3L1 pathway (8, (11) (12) (13) . The targeted deletion of CX3CR1 inhibits these processes and also prolongs cardiac allograft survival in mouse model system (14) . In addition, it has been shown that CX3CR1/CX3CL1 response involves actin polymerization during cell movement (15, 16) . The CX3CR1 belongs to the family of G protein-coupled receptors (17) , which upon ligand binding undergo conformational changes into the guanine nucleotide exchange factors (GEFs; 18; Fig.8 ). The GEFs, in turn, activate RhoA and thus, indirectly, regulate actin polymerization pathway (19) . Previous studies on chronic rejection showed that RhoA/ROCK pathway interference (using Y-27632 inhibitor) disrupts actin and actin-related cell functions (20) (21) (22) (23) , affects macrophages and abrogates chronic rejection of mouse cardiac allografts (24) .
Recently, we also showed that RhoA deletion causes disregulation of RhoA pathway and changes actin organization in murine peritoneal macrophages (25) .
All these data prompted us to study how the targeted deletion of RhoA in the monocyte/macrophage lineage affects macrophages and chronic rejection of cardiac allografts in transgenic mouse model system. Here we show that deletion of RhoA down-regulates monocyte/macrophage CX3CR1/CX3CL1 signaling, inhibits macrophage infiltration and vessel occlusion, and abrogates chronic rejection of mouse cardiac allografts.
Materials and Methods
Animals, generation of RhoA-deficient mice, and genotyping. 
Breeding and all experiments were performed according to The Methodist

Histology, Neointimal index, collagen deposition and immunostaining
The paraffin sections of transplanted hearts were stained with VVG (VerhoeffVan Gieson) and Trichrome Masson and immunostaining as described in Liu et al. (25) . The VVG stained sections were used to calculate neointimal index (vessel occlusion). For comparison of vessel occlusion we inspected 5-8 vessels from each mouse (3 mice per experimental group), and 20 vessels were used to calculate neointimal indexes. Actin, vinculin, transferrin receptor and CX3CR1
immunostaining were performed as in Liu et al (24, 25) . The following antibodies against macrophage markers were used: F4/80 (BioLegend, USA or Serotec, USA), Mac-2 (Cedarlane Laboratories, USA). Transferrin Receptor / CD71 was from ThermoFisher Scientific, USA, CX3CR1 (H-70) from Santa Cruz, USA and secondary antibodies were from ThermoFisher Scientific. In immunostained slides, cells were counted in 3-12 independent samples and statistical significance of cell percentage differences was evaluated using student t test.
Wild type and RhoA deleted mice (3-5 of each) were sacrificed after 30-50 days post-transplantation. The neointimal index and collagen occupied area in Masson stained samples was calculated (collagen/total area) using Image-pro plus 6.0 as decscribed previously (25) .
Apoptosis assay
Fixed heart sections were stained with Tunel-DeadEnd™ Fluorometric TUNEL System (Promega, USA) according to the manufacturer protocol and immunostained with Mac-2 primary antibody and Alexa Fluor 546 conjugated goat anti rat IgG (Life Technologies, USA) secondary antibody.
Peritoneal macrophage apoptosis assay was performed as described in Liu et al. 
Results
Deletion of RhoA inhibits chronic rejection and macrophage infiltration of cardiac allograft
We previously showed that macrophages isolated from Lyz2 Cre+/-RhoA flox/flox mice were deficient in expression of RhoA mRNA and its protein (29 (Fig.1A) but histologically, the heart allografts demonstrated prominent vascular occlusion (Fig.1B, D) and fibrosis (Fig.1E, G) , which are characteristic for chronic rejection, impaired heart muscle integrity (Fig.1H) , and heavy total and inflammatory macrophages infiltration ( Fig. 2A , C, E). In contrast, cardiac allografts from Lyz2 Cre+/-RhoA flox/flox recipients treated with CTLA4-Ig showed not only prolonged survival (Fig. 1A ) but also the abrogation of chronic rejection with low (statistically significant) vascular occlusion (Fig.1C, D) and markedly improved heart muscle integrity (Fig.1I) . Histological examination showed that these allografts had reduced, although statistically nonsignificant, collagen deposition (Fig.1F, G ). The immunostaining with total (F4/80) and activated macrophage (Mac2) markers showed that allografts from Lyz2
Cre+/-RhoA flox/flox recipients had statistically significant reduction of infiltration with total and activated (inflammatory) macrophages (Fig. 2B , D, E).
Cardiac allografts show negligible apoptosis and RhoA deleted
macrophages are not more prone to apoptosis induction than control macrophages.
It is known that RhoA pathway regulates apoptosis (27) . Thus, one of the explanations for low macrophage infiltration of the allografts from RhoA-deleted 
RhoA deletion does not impair bone marrow proliferation and frequency of blood monocytes
Knowing that RhoA besides apoptosis also regulates cell proliferation (28) showed that deletion of RhoA down regulated CX3CR1 protein expression in peritoneal macrophages while the expression of CCR2 receptor remained unchanged (Fig.5) . We also found that upon RhoA deletion there is up-regulation of CX3CR1 mRNA (Fig.5 I) . We believe that the up-regulation of CX3CR1 mRNA is a compensatory response to the insufficient level of receptor protein and faulty receptor recycling (see below and Discussion). Taken together all these results strongly suggest that the impairment of fractalkine (CX3CL1/CX3CR1) chemotactic pathway is the main reason for the low abundance of macrophages in the allografts transplanted into RhoA-deleted recipients.
RhoA deletion changes actin cytoskeleton and impairs CX3CR1 association with endosomes
Actin staining of RhoA-deleted macrophages showed profound changes in actin cytoskeleton organization caused by inability to disassembly focal adhesions and retract the tail (described in detail in Liu et al. 25 and The fractalkine, which is expressed by endothelial cells of the blood vessel walls, recruits macrophage precursors (monocytes) and macrophages in the vicinity of blood vessels where they mount inflammatory responses , collagen deposition (fibrosis) and neointimal hyperplasia (11, 12, (31) (32) (33) . Recent studies indicate that CX3CR1/CX3CL1 pathway is responsible for the monocyte/macrophage directed migration into artherosclerotic plaque (8) and for smooth muscle differentiation and neiontima formation in vessel wall after the injury (11-13). It has been also shown that CX3CR1 knockout prolongs survival of cardiac allografts in mouse model system (14) Recently, we showed that RhoA pathway interference affected actin organization and macrophage phenotype (24, 25) . However, we
showed that in in vitro assay, the RhoA-deleted peritoneal macrophages were able to degrade extracellular matrix (a prerequisite for intra-and inter-tissue migration) and migrate normally (25) . Although this observation does not prove that RhoA-deleted macrophages can migrate normally in vivo, it strongly suggests that low macrophage infiltration in the allografts in RhoA-deleted mice is not caused by the impairment of macrophage migration but rather a defect in their recruitment. In addition, although we have not directly proven that macrophages actually cause chronic rejection, our findings indicate that macrophages are crucial for development of chronic rejection.
Considering all these data we propose the following scenario of events (Fig. 8,   9 ). Under naïve conditions (untransplanted mice) majority of bone marrow derived and blood monocytes and peritoneal macrophages express CX3CR1
receptors (8) . The organ injury such as transplantation results in increased production and release of inflammatory chemokine (CX3CL1, fractalkine) and high recruitment of monocytes/macrophages to the allograft. The interaction of CX3CR1 receptor (which is the G coupled protein) with CX3CL1 causes conformational changes of the receptor into GEF (Fig. 8) . The GEF activates
RhoA, which in turn, changes actin polymerization/dynamics, which promotes monocyte/macrophage migration to the blood vessel wall (main source of CX3CL1), differentiation of smooth muscle cells in the wall and hyperplasia of neointima. This, over time, occludes blood vessels and leads to chronic rejection/organ failure (Fig. 8, 9 ). The deletion of RhoA causes faulty RhoAdependent actin polymerization/dynamics, which interferes with normal recycling (and transcription/translation) of CX3CR1 receptors and leads to decreased expression of CX3CR1 in monocytes and macrophages (Fig.8) , which in turn reduces CX3CR1/CX3CL1-dependent recruitment to the allografts. Our study showed that deletion of RhoA caused decrease in CX3CR1 protein expression and increase in CX3CR1 mRNA level. It is known that the recycling/turnover of G protein coupled receptors, such as CX3CR1 occurs through endocytotic/exocytotic pathway and is actin-and RhoA-dependent (29, 30 34).
Proper receptor recycling (turnover), in turn, determines receptor's expression at transcriptional (mRNA) and translational (protein) level. We showed that RhoA deletion disrupted CX3CR1 association with endosomes. Thus, we believe that the increase in the expression of CX3CR1 mRNA, which we had observed in RhoA-deleted macrophages, is a compensatory response to the low expression of its protein resulting from a faulty CX3CR1 turnover (Fig. 8 ). All these defects, upon transplantation, lead to a dramatic decrease in the abundance of CX3CR1 positive macrophages in the allograft and its vasculature, decrease in CX3CR1/CX3CL1-dependent neointimal hyperplasia and resulted in abrogation of chronic rejection (Fig. 8, 9 ).
It is known that the monocyte/macrophage inflammatory response does not depend exclusively on CX3CR1/CX3CL1 signaling but also, among multitude of other pathways, on the CCR2/CCL2 pathway (8, 35) . The CCR2 receptor belongs to CC chemokine receptors family, which similar to CX3CR1 are the G protein-coupled proteins involved in regulation of, and regulated by, the RhoA pathway. Our study showed that while RhoA-deletion had impaired CX3CR1 it had only slight effect on CCR2 expression in blood monocytes. The question is why RhoA-deletion has different effect on two different receptors from the (broadly) same family of G protein-coupled receptors. Although answering this question requires further study, one of the possible explanations is that the changes caused by RhoA deletion are detrimental to the receptors with a specific structure only. Another explanation is that because the CCL2/CCR2 mediates RhoA activity through Smad3/ MAPK (36) and/or PKC signaling (37) while the CX3CR1/CX3CL1 interactions with RhoA pathway are more direct (12) the CX3CR1/CX3CL1 pathway is more "sensitive" to RhoA deletion.
Another fascinating possibility, which would explain the difference between the involvement and importance of CX3CR1 versus CCR2 pathways in chronic rejection may be related to selective utilization of CX3CR1 pathway, which was described in development of atherosclerotic plaque (8) or the phenomenon of CCR2 to CX3CR1 receptor switching, which was described by Barlic et al. (38).
These authors showed that human macrophages present in human coronary artery have ability to switch CCR2 off and CX3CR1 on, which causes inhibition of CCR2-dependent migration in favor of CX3CR1-dependent macrophage accumulation in the vessel wall. If such switch also occurs during anti-allograft immune response than it would be quite understandable why the inhibition of CX3CR1 but not the CCR2 pathway had such profound inhibitory effect on neointimal hyperplasia and chronic rejection.
Recent study from our laboratory (25) also showed that RhoA deletion upregulates the activity of its downstream effector ROCK1 in peritoneal macrophages, and that this effect depends on non-apoptotic Caspase-3. Thus, in the future, it will be important to study if and how Caspase-3 regulates monocyte/macrophage CX3CR1/CX3CL1 pathway during chronic rejection.
Further studies are needed to eliminate a very remote possibility that the differences between the macrophage number in the grafts of RhoA-deficient and wild type recipients might in part reflect differences in severity of ischemia In wild type macrophages CX3CR1 co-localized with endosomes, while in RhoAdeleted macrophages the co-localization with endosome is disrupted and CX3CR1 localizes at the macrophage plasma membrane (arrows). Bar is equal to 50 μm. 
